CA-AVIATRIX
9.3.2021 15:02:11 CET | Business Wire | Press release
Aviatrix , the cloud network platform, today announced the availability of the 2021 Forrester's Total Economic Impact™ (TEI) Study commissioned by Aviatrix, conducted independently by Forrester Consulting in January 2021. The TEI Study is based on Forrester's in-depth interviews with Aviatrix customers and provides a quantitative, business value justification designed to help IT leaders. It demonstrates a composite cost-savings and business benefits analysis interviewed customers realized by leveraging the Aviatrix cloud network platform and provides a model for determining economic value in any organization.
The complete results of the TEI Study of Aviatrix can be found and downloaded here , where readers will learn how Aviatrix customers leverage more advanced cloud networking, security, and operational visibility for their cloud and multi-cloud network environments, helping them generate new revenue and ensure operational efficiency at significantly lower costs.
Key highlights of the TEI Study on Aviatrix cloud network platform Include:
- Aviatrix pays for itself more than 2x in the span of three years (222% ROI)
- Over $3 million in revenue and margin gains from new and existing customers attributed to multi-cloud readiness and faster time-to-market
- Over $1 million in cost savings from operational efficiency and resource re-allocation
- Over $4 million in business benefits and cost savings over three years
Cloud infrastructure is becoming the norm for many organizations. Decision makers may plan to focus on a single cloud platform, but they often need to support many due to acquisitions, client requirements, or app developer preferences. Each cloud service provider comes with its own processes, native constructs and tools that can slow cloud network operations. The Aviatrix cloud network platform helps organizations automate and control cloud network infrastructure, maintain security compliance, and respond to clients much faster.
Aviatrix customers saw significant benefits after deploying the company’s cloud network platform:
- “Without Aviatrix, it would have taken an extra year and twice the staff” — Sr. Infrastructure Architect, insurance company.
- “We have been able to open new lines of business and keep up with increased demand” — Assistant Director of Cloud Architecture and Engineering, manufacturer.
- “We can shine a light in the dark corners of public cloud [with Aviatrix]” — Senior Cloud Architect, business software and services provider.
- “With Aviatrix, we are saving millions” — Assistant Director of Cloud Architecture and Engineering, manufacturer.
“We’re very pleased with the overall results of the Forrester TEI Study,” said Rod Stuhlmuller, Vice President of Product Marketing at Aviatrix. “The quantifiable data truly highlights the benefits our customers receive using the Aviatrix cloud network platform. Furthermore, our customers achieve these benefits in both single and multi-cloud environments. As more enterprises adopt a multi-cloud strategy, Aviatrix’s market leading solutions will be the foundation for demonstratable economic gains.”
Executive Summary Video of the TEI Study on Aviatrix: (5 mins)
Watch guest speaker Sean Owens, Forrester’s Principal Consultant, and leader of the TEI of Aviatrix cloud network platform study, provide an executive summary of the study’s methodology, key findings, and quantified results. View video here.
About Aviatrix
Aviatrix cloud network platform delivers advanced networking, security and operational visibility and control required by enterprises, with the simplicity, automation, and agility of cloud. More than 500 customers worldwide leverage Aviatrix and its proven multi-cloud network reference architecture to design, deploy and operate a repeatable network and security architecture that is consistent across any public cloud. Combined with the industry’s first and only multi-cloud networking certification (ACE ), Aviatrix is empowering IT to lead and accelerate the transformation to the cloud. Learn more at aviatrix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210309005348/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
